SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-037533
Filing Date
2023-10-17
Accepted
2023-10-17 17:27:10
Documents
15
Period of Report
2023-10-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43610
2 ex10-1.htm EX-10.1 43477
3 ex99-1.htm EX-99.1 17776
  Complete submission text file 0001493152-23-037533.txt   328615

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lixt-20231013.xsd EX-101.SCH 3519
5 XBRL DEFINITION FILE lixt-20231013_def.xml EX-101.DEF 26564
6 XBRL LABEL FILE lixt-20231013_lab.xml EX-101.LAB 36548
7 XBRL PRESENTATION FILE lixt-20231013_pre.xml EX-101.PRE 25188
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 4825
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 231330428
SIC: 2834 Pharmaceutical Preparations